Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis

Authors
Category Primary study
ConferenceMSmilan2023
Year 2023
This article has no abstract
Epistemonikos ID: 93f7750e8eab02a95731351f9d4a6b3f8cb0bf03
First added on: Jan 10, 2026